Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Precision BioSciences, Inc. Common Stock

Precision BioSciences, Inc. (Nasdaq: DTIL) is a pre-clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

Aliment Capital

The Longevity Fund

RA Capital Management

Leerink Partners

Ridgeback Capital

Alexandria Venture Investments

Cormorant Asset Management

Ditch Plains Capital Management LP

DUMAC

F-Prime Capital

Precision BioSciences, Inc.

Following pre-IND regulatory feedback from the FDA and ex-US regulators, we are advancing PBGENE-HBV toward an IND/CTA filing in 2024. 
 
The goal of our #investigational PBGENE-HBV program is to achieve a functional cure for patients with Chronic Hepatitis B. Hear from Chari Cohen, president of the Hepatitis B Foundation, on what this could mean for those living with HBV.
 
https://bit.ly/48fEVrt

How is ARCUS positioned to move beyond simple gene knockouts and tackle more sophisticated edits like gene elimination, excision, and insertion? 

Hear from Precision CRO, Jeff Smith in his #JPM2024 interview with pharmaphorum as they discuss the future of gene editing with ARCUS and going beyond CRISPR for in vivo gene editing.

Watch:
https://bit.ly/3TXFhQ4

Good news! We’ve completed a licensing deal with TG Therapeutics, Inc. to develop azer-cel for autoimmune diseases.

The deal extends our cash runway into the first half of 2026 and funds our wholly owned In vivo gene editing programs PBGENE-HBV for chronic hepatitis B and PBGENE-PMM for primary mitochondrial myopathy through Phase I Clinical Data.

Precision remains focused on capitalizing on the utility of ARCUS for gene elimination, gene excision and gene insertion through the advancement of our wholly owned and partnered programs.

Read more #JPM24: https://bit.ly/48IqY63

Precision CEO, Michael Amoroso, will speak at Longwood Healthcare Leaders in San Francisco on “The Future of Genetic Therapies” – joining other key industry thought leaders to discuss a wide range of issues affecting biopharma and healthcare. #longwoodhealthcareleaders

Learn more: https://bit.ly/3Tzx7gz

Precision’s Wendy Shoop, PhD., and University of Miami’s Carlos Moraes spoke with BioWorld about the recent publication in Nature Metabolism on mitoARCUS and our #investigational approach to primary mitochondrial myopathy. Read more from their conversation here: https://bit.ly/48g3Bk6

We’re pleased to announce the approval of the first clinical trial application of an ARCUS gene insertion program. Our partner iECURE received clearance from the Australian Therapeutic Goods Administration for a Phase 1/2 trial of ECUR-506, incorporating an ARCUS nuclease for the treatment of OTC deficiency. https://bit.ly/3NsrYDc

At this year’s Hep DART 2023, our Chief Research Officer and co-founder, Jeff Smith, & HBV Research Lead, Emily Harrison, presented on our #investigational PBGENE-HBV program. 

Learn more about our in vivo gene editing: https://bit.ly/41dIegX

We’re proud to share new research published in Nature Metabolism alongside Carlos Moraes that supports the development of mitoARCUS as an in vivo gene editing therapeutic for mitochondrial DNA diseases associated with the m.3243A>G mutation. Read more: https://bit.ly/3tcryK2.

In honor of #Thanksgiving tomorrow we want to thank all our employees for their dedication and celebrate our stakeholders for their investment and belief in Precision. It’s been an active year for us, and we’re looking forward to closing out the year strong.

We’re excited to share that we presented at the Sidoti & Company, LLC November Conference earlier today on our innovative ARCUS technology. ARCUS is capable of more sophisticated gene edits, with a focus on insertions, excisions and eliminations. That is the #ARCUS difference. See a recording of the presentation at the link below: https://bit.ly/3QZ4WWx

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	1.81M -	2.22M 22.81%	2.04M 8.16%	792K 61.12%	1.14M 44.44%	1.23M 7.08%	2.97M 142.29%
accumulated other comprehensive income loss	-3.19M -	-5.48M 71.75%
cash and cash equivalents	62.80M -	103.19M 64.31%	180.89M 75.29%	89.80M 50.36%	143.66M 59.98%	189.58M 31.96%	116.68M 38.45%
cash and short term investments	62.80M -	103.19M 64.31%	180.89M 75.29%	89.80M 50.36%	143.66M 59.98%	189.58M 31.96%	116.68M 38.45%
common stock						1K -	1K 0%
deferred revenue	5.82M -	8.44M 44.85%	16.49M 95.42%	30.24M 83.40%	21.24M 29.74%	46.19M 117.44%	12.04M 73.95%
deferred revenue non current	88.60M -	82.81M 6.53%	65.89M 20.42%	53.93M 18.16%	77.02M 42.82%	92.87M 20.59%	73.08M 21.31%
deferrred tax liabilities non current
goodwill
goodwill and intangible assets	90K -	1.47M 1,528.89%	1.43M 2.32%	1.37M 4.12%	2.05M 49.16%	1.35M 34.18%	400K 70.33%
intangible assets	90K -	1.47M 1,528.89%	1.43M 2.32%	1.37M 4.12%	2.05M 49.16%	1.35M 34.18%	400K 70.33%
inventory			9.50M -	5.76M 39.33%	17.43M 202.57%	7.55M 56.68%
long term debt				8.59M -	7.29M 15.08%	25.00M 242.87%
long term investments					6.84M -	4.75M 30.61%	3.21M 32.48%
net debt	-62.80M -	-103.19M 64.31%	-180.89M 75.29%	-79.28M 56.17%	-134.55M 69.72%	-162.54M 20.80%	-115.55M 28.91%
net receivables	22K -	1.03M 4,568.18%	965K 6.04%	10M 936.27%	488K 95.12%	720K 47.54%	901K 25.14%
other assets
other current assets	1.51M -	11.46M 660.12%	2.32M 79.71%	4K 99.83%	169K 4,125%	1.26M 643.79%	18.78M 1,394.03%
other current liabilities	67K -	170K 153.73%	1.58M 831.76%	9.87M 522.98%	11.77M 19.27%	10.21M 13.25%	33.85M 231.55%
other liabilities
other non current assets	124K -	312K 151.61%	558K 78.85%	1.72M 208.42%	4.64M 169.67%	9.80M 111.25%	5.21M 46.81%
other non current liabilities	1.25M -	1.76M 40.42%	4.09M 132.76%	392K 90.42%	44K 88.78%	201K 356.82%	17.85M 8,781.09%
othertotal stockholders equity	15.93M -	130.63M 719.93%	315.38M 141.43%	330.50M 4.79%	407.84M 23.40%	488.74M 19.84%	508.49M 4.04%
preferred stock	3K -
property plant equipment net	8.14M -	21.15M 159.89%	39.57M 87.12%	41.50M 4.87%	29.33M 29.32%	23.16M 21.03%	14.60M 36.97%
retained earnings	-39.11M -	-85.19M 117.81%	-177.07M 107.86%	-286.07M 61.56%	-316.68M 10.70%	-428.31M 35.25%	-489.63M 14.32%
short term debt	1.51M -	3.25M 115.87%	6.83M 109.94%	1.93M 71.68%	1.82M 5.74%	2.04M 11.80%	1.13M 44.38%
short term investments
tax assets					6.88M -
tax payables
total assets	72.68M -	138.60M 90.69%	235.23M 69.72%	150.16M 36.17%	211.50M 40.85%	238.17M 12.61%	159.78M 32.91%
total current assets	64.33M -	115.67M 79.81%	193.67M 67.43%	105.56M 45.49%	161.75M 53.23%	199.10M 23.09%	136.36M 31.51%
total current liabilities	9.20M -	14.07M 52.94%	26.93M 91.35%	42.83M 59.03%	35.98M 15.99%	59.66M 65.83%	49.99M 16.22%
total debt				10.52M -	9.11M 13.37%	27.04M 196.68%	1.13M 95.81%
total investments					6.84M -	4.75M 30.61%	3.21M 32.48%
total liabilities	99.05M -	98.64M 0.41%	96.92M 1.74%	105.73M 9.09%	120.33M 13.81%	177.74M 47.71%	140.92M 20.71%
total liabilities and stockholders equity	72.68M -	138.60M 90.69%	235.23M 69.72%	150.16M 36.17%	211.50M 40.85%	238.17M 12.61%	159.78M 32.91%
total non current assets	8.35M -	22.93M 174.52%	41.56M 81.29%	44.59M 7.30%	49.74M 11.55%	39.06M 21.47%	23.42M 40.04%
total non current liabilities	89.85M -	84.56M 5.88%	69.99M 17.24%	62.90M 10.12%	84.35M 34.09%	118.07M 39.98%	90.93M 22.99%
total stockholders equity	-26.37M -	39.96M 251.54%	138.31M 246.13%	44.42M 67.88%	91.17M 105.22%	60.43M 33.71%	18.86M 68.79%

COM:PRECISIONBIOSCIENCES

Precision BioSciences, Inc.

Last Close

6.50

22/11 21:00

Market Cap

55.69M

Beta: -

Volume Today

105.61K

Avg: -

Preview